Biotech Reports Positive Preclinical COVID-19 Study Results
Source: Streetwise Reports  (6/16/21)
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. More >

Immuno-oncology Firm Advances Lead Asset in Mesothelioma
Source: Streetwise Reports  (6/16/21)
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. More >

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial
Source: Streetwise Reports  (6/16/21)
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. More >

Clearside Biomed Shares Rise 37% on Positive Data in Phase 1/2a Wet AMD Trial
Source: Streetwise Reports  (6/15/21)
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints. More >

Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure
Source: Streetwise Reports  (6/14/21)
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. More >

Sorrento's COVID Test Approved in Mexico
Source: Streetwise Reports  (6/9/21)
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. More >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios
Source: Streetwise Reports  (6/9/21)
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. More >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom
Source: McAlinden Research for Streetwise Reports  (6/4/21)
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. More >

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study
Source: Streetwise Reports  (6/3/21)
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. More >

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
Source: Streetwise Reports  (6/3/21)
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. More >

Innovative Life Sciences Company Boosts Immune Function in Livestock Without the Use of Antibiotics
Source: Streetwise Reports  (6/2/21)
Avivagen's OxC-betaâ„¢ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters. More >

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program
Source: Streetwise Reports  (6/2/21)
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. More >

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer
Source: Streetwise Reports  (6/2/21)
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. More >

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma
Source: Streetwise Reports  (5/26/21)
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. More >

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'
Source: Streetwise Reports  (5/26/21)
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. More >

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug
Source: Streetwise Reports  (5/24/21)
Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. More >

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD
Source: Streetwise Reports  (5/19/21)
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. More >

Analyst Highlights Two Key Catalysts for Biotech
Source: Streetwise Reports  (5/19/21)
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. More >

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study
Source: Streetwise Reports  (5/18/21)
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." More >

Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder
Source: Streetwise Reports  (5/17/21)
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. More >

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year
Source: Streetwise Reports  (5/13/21)
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.
More >

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
Source: Streetwise Reports  (5/13/21)
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Life Sciences Firm Is at 'an Inflection Point with Significant Sales Increases Just around the Corner'
Source: Streetwise Reports  (5/12/21)
Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico. More >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
Source: Streetwise Reports  (5/5/21)
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. More >